SML2952
Tasisulam
≥98% (HPLC)
别名:
LY 573636, LY-573636, LY573636, N-(2,4-Dichlorobenzoyl)-5-bromothiophene-2-sulfonamide, N-(5-Bromothiophen-2-ylsulfonyl)-2,4-dichlorobenzamide, N-[(5-Bromo-2-thienyl)sulfonyl]-2,4-dichlorobenzamide
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C11H6BrCl2NO3S2
化学文摘社编号:
分子量:
415.11
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
Tasisulam, ≥98% (HPLC)
SMILES string
[S](=O)(=O)(NC(=O)c2c(cc(cc2)Cl)Cl)c1[s]c(cc1)Br
InChI
1S/C11H6BrCl2NO3S2/c12-9-3-4-10(19-9)20(17,18)15-11(16)7-2-1-6(13)5-8(7)14/h1-5H,(H,15,16)
InChI key
WWONFUQGBVOKOF-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
RNA binding motif protein 39 (RBM39; CAPERα, HCC1) degradation-inducing SPLAM (SPLicing inhibitor sulfonAMide).
Tasisulam (LY573636) is a SPLAM (SPLicing inhibitor sulfonAMide) that bridges RNA binding motif protein 39 (RBM39; CAPERα, HCC1) and DCAF15 for interaction, thereby promoting (CUL4-DDB1-DDA1-DCAF15) E3 ubiquitin ligase complex-mediated RBM39 ubiquitination and subsequent proteasomal degradation. Tasisulam exerts selective toxicity in parental HCT116 cancer cultures (IC50 = 6.5 μM), but not those harboring non-CUL4-DCAF15-associating RBM39 G268V mutant even at a high concentration of 50 μM.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Ting Han et al.
Science (New York, N.Y.), 356(6336) (2017-03-18)
Indisulam is an aryl sulfonamide drug with selective anticancer activity. Its mechanism of action and the basis for its selectivity have so far been unknown. Here we show that indisulam promotes the recruitment of RBM39 (RNA binding motif protein 39)
Everett J Perkins et al.
European journal of drug metabolism and pharmacokinetics, 43(3), 355-367 (2017-11-10)
Cytochrome P450 2C9 (CYP2C9) is involved in the biotransformation of many commonly used drugs, and significant drug interactions have been reported for CYP2C9 substrates. Previously published physiologically based pharmacokinetic (PBPK) models of tolbutamide are based on an assumption that its metabolic
Timothy Meier et al.
Molecular cancer therapeutics, 10(11), 2168-2178 (2011-09-10)
LY573636-sodium (tasisulam) is a small molecule antitumor agent with a novel mechanism of action currently being investigated in a variety of human cancers. In vitro, tasisulam induced apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell
Talin Haritunians et al.
Oncology reports, 20(5), 1237-1242 (2008-10-25)
LY573636-sodium is a promising anti-tumor agent, which causes growth arrest and apoptosis of a variety of human solid tumors in vitro and in vivo. Moreover, studies have shown that the compound is selectively toxic towards tumor cells over their normal
Tyler B Faust et al.
Nature chemical biology, 16(1), 7-14 (2019-11-07)
The investigational drugs E7820, indisulam and tasisulam (aryl-sulfonamides) promote the degradation of the splicing factor RBM39 in a proteasome-dependent mechanism. While the activity critically depends on the cullin RING ligase substrate receptor DCAF15, the molecular details remain elusive. Here we
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持